Is BEACOPP better than ABVD?

被引：10

作者：

Cheson B.D. ^{[1
]}

机构：

[1] Georgetown University Hospital, Washington, DC 20007, 3800 Reservoir Road, N.W.

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 3期

关键词：

Gemcitabine; Bleomycin; German Hodgkin Study Group; Diehl Versus; Freedom From Treatment Failure;

D O I：

10.1007/s11899-007-0022-2

中图分类号：

学科分类号：

摘要：

The majority of patients with advanced Hodgkin's lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine). However, almost 20% of patients fail to achieve a complete remission and almost 40% relapse with prolonged follow-up. BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) was developed by the German Hodgkin's Study Group to improve on standard therapy by intensifying treatment and substituting the active agent etoposide for vinblastine and dacarbazine. Promising results led to the HD9 trial, in which escalated BEACOPP was superior to COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbazine/ABVD). Nevertheless, escalated BEACOPP is myelosuppressive and is associated with an increased risk of secondary malignancies. Modifications of BEACOPP have been developed in an attempt to increase efficacy and reduce the adverse effects. Whether BEACOPP should be selected in preference to ABVD may be determined by clinical stage, patient age, and other risk factors. The answer to whether escalated BEACOPP is superior to ABVD will require the results of an ongoing randomized trial. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：161 / 166

页数：5

共 31 条

[1]

DeVita Jr V.T., Serpick A.A., Combination chemotherapy in the treatment of advanced Hodgkin's disease, Ann Intern Med, 73, pp. 881-895, (1970)

[2]

DeVita Jr V.T., Simon R.M., Hubbard S.M., Et al., Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute, Ann Intern Med, 92, pp. 587-595, (1980)

[3]

Santoro A., Bonfante V., Bonadonna G., Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease, Ann Intern Med, 96, pp. 139-143, (1982)

[4]

Bonadonna G., Zucali R., Monfardini S., Et al., Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP, Cancer, 36, pp. 252-259, (1975)

[5]

Santoro A., Bonadonna G., Bonfante V., Valagussa P., Alternating drug combinations in the treatment of advanced Hodgkin's disease, N Engl J Med, 306, pp. 770-775, (1982)

[6]

Canellos G.P., Anderson J.R., Propert K.J., Et al., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD, N Engl J Med, 327, pp. 1478-1484, (1992)

[7]

Bonadonna G., Valagussa P., Santoro A., Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease, Ann Intern Med, 104, pp. 739-746, (1986)

[8]

Klimo P., Connors J.M., MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease, J Clin Oncol, 3, pp. 1174-1182, (1985)

[9]

Glick J.H., Young M.L., Harrington D., Et al., MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial, J Clin Oncol, 16, pp. 19-26, (1998)

[10]

Duggan D.B., Petroni G.R., Johnson J.L., Et al., Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial, J Clin Oncol, 21, pp. 607-614, (2003)

← 1 2 3 4 →